This product is a gastrin receptor antagonist, which can significantly inhibit the secretion of gastric acid and pepsin caused by gastrin, but has no significant effect on the gastric acid secretion caused by histamine and vagus nerve stimulation. It can increase the content of hexosamine in the gastric mucosa, promote glycoprotein synthesis, protect the gastric mucosa and promote healing, improve the symptoms of peptic ulcer and promote ulcer healing. The use of this product to treat peptic ulcer and gastritis does not cause rebound of gastric acid secretion, and gastric acid secretion can remain at a normal level for up to half a year after the treatment is terminated. In addition, this product has a choleretic effect: by stimulating bile acid-independent bile secretion, changing the stone-forming factors in bile, and by antagonizing CCK to inhibit the gallbladder contraction-promoting effect of endogenous CCK, the gallbladder capacity is expanded, thereby preventing stone formation.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. It has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus aureus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. It also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis.